Genomics of immune molecules: early detection of cognitive decline and new therapeutic interventions

References

• Katzman RN. Medical progress: Alzheimer's disease. N Engl. I Med. 274, 964–973 (1986).
   Google Scholar
• Rubinsztein DC. The genetics of Alzheimer's disease. Frog. Neurobiol 52, 447–454 (1997).
   Google Scholar
• Corder EH, Saunders AM, Strittmatter WJ et al Gene dose of apolipoprotein E Type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261,921–923 (1993).
   PubMed Web of Science ®Google Scholar
• Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342,697–699 (1993).
   PubMed Web of Science ®Google Scholar
• •Important papers showing the association of the APOE 4 allele with increased risk of developing AD.
   Google Scholar
• Breitner JCS, Gau BA, Welsh IKA et al Inverse association of anti-inflammatory treatments and Alzheimer's disease. Neurology 44, 227–232 (1994).
   PubMed Web of Science ®Google Scholar
• McGeer PL, Schulzher M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology47 425–432 (1996).
   Google Scholar
• •Extensive study suggesting a link between AD and inflammation.
   Google Scholar
• Beach TG, Walker R, McGeer EG. Patterns of gliosis in Alzheimer's disease and aging cerebrum. Gila 2,420–436 (1989).
   Google Scholar
• McGeer PL, Rogers J, McGeer EG. Neuroimmune mechanisms in Alzheimer's disease pathogenesis. Alzheimer Dis. Assoc. Disor. 8,149–158 (1994).
   PubMed Web of Science ®Google Scholar
• McGeer EG, McGeer PL. Chronic inflammation in Alzheimer's disease offers therapeutic opportunities. Expert Rev Neurotherapeuticsl, 53–60 (2001).
   Google Scholar
• Kelso A. Cytokines: principles and prospect. Immunol Cell Biol. 76,300–317 (1998).
   PubMedGoogle Scholar
• Dinarello CA. Interleukin-1, interleukin-1 receptor and interleukin-1 receptor antagonist. Int. Rev Immunol 16, 457–499 (1998).
   Google Scholar
• Gauldie J, Richards C, Baumann H. IL-6 and the acute phase reaction. Res. Immunol 143,755–759 (1992).
   Google Scholar
• Baumann H, Gauldie J. The acute phase response. Immunol Today 15,74–80 (1994).
   PubMedGoogle Scholar
• Bauer J, Strauss S, Schreiter-Gasser U et al Interleukin-6 and a-2-macroglobulin indicate an acute phase state in Alzheimer's disease cortex. FEBS Lett. 285,111–114 (1991).
   PubMed Web of Science ®Google Scholar
• Griffin W Stanley LC, Ling C et al. Brain inteneukin-1 and S-100 immunoreactivity elevated in Down's syndrome and Alzheimer's disease. Proc. Natl Acad. Sci. USA 86, 7611–7615 (1989).
   Google Scholar
• Sheng JC, Griffin WS, Royston MC, Mrak RE. Distribution of interleukin-l-immunoreactive microglia in cerebral cortical layers: implication for neuritic plaque formation in Alzheimer's disease. Neuropathol Appl. Neurobio124,278–283 (1998).
   Google Scholar
• Ershler WB. Interleukin-6: a cytokine production in mononuclear cells of healthy elderly people. Eur. Immuno123, 2375–2378 (1993).
   Google Scholar
• Fagiolo U, Cossarizza A, Scala E et al Increased cytokine production in mononuclear cells of elderly people. Eur.J. Immunol 23,2375–2378 (1993).
   PubMed Web of Science ®Google Scholar
• Strauss S, Bauer J, Ganter U, Jonas U, Berger M, Volk B. Detection of interleukin-6 and a-2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab. Invest. 66,223-230 (1992).
   Google Scholar
• Huell M, Strauss S, Volk B, Berger M, Bauer J. Interleukin-6 is present in early stages of plaque formation and is restricted to the brain of Alzheimer's disease patients. Acta Neuropathol 89,544–551 (1995).
   Google Scholar
• Griffin WS, Sheng JG, Royson MC et al Glial-neuronal interactions in Alzheimer's disease: the potential role of a `cytokine cycle' in disease progression. Brain. Pathol 8,65–72 (1998).
   PubMed Web of Science ®Google Scholar
• McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer's disease. Exp. Cerontol 33,371–378 (1998).
   PubMed Web of Science ®Google Scholar
• Alvarez XA, Franco A, Fernandez-Novoa F, Cacabelos R. Blood levels of histamine, IL-1 beta and TNF-alpha in patients with mild to moderate Alzheimer's disease. Mal Chem. Neuropathol 29,237–252 (1996).
   Google Scholar
• Bonaccorso S, Lin A, Song C et al Serotonine-immune interactions in elderly volunteers and in patients with Alzheimer's disease (DAT):lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT. Aging (Milane) 10, 316–323 (1998).
   PubMedGoogle Scholar
• Kalman J, Juhasz A, Laird G et al Serum interleukin-6 levels correlate with the severity of the dementia in Down's syndrome and Alzheimer's disease. Acta Neural. Scantl 96,236–240 (1997).
   Google Scholar
• Licastro F, Morini MC, Polazzi E, Davis U. Increased serum alpha-1-antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response. Neuroimmunol 57,71–75 (1995).
   PubMed Web of Science ®Google Scholar
• •First paper suggesting the presence of a nonclassical form of inflammation in AD.
   Google Scholar
• Singh VK, Guthikonda P. Circulating cytochines in Alzheimer's disease. PTchiatr. Res. 31,657–660 (1997).
   PubMed Web of Science ®Google Scholar
• Angelis P, Sharf S, Mander A, Vajda F, Christophidis N. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease. Neurosci. Lett. 244, 106–108 (1998).
   Google Scholar
• Van Duijn CM, Hofman A, Nagelkerken L. Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. Neumsci. Lett. 108,350-354 (1990).
   Google Scholar
• Abraham CR, Shirahama T, Potter H. Alpha-l-antichymotrypsin is associated solely with amyloid and cell localization of alpha-1-antichymotrypsin. Neurobial Aging 1,123–129 (1990).
   Google Scholar
• Licastro F, Mallory M, Hansen LA, Malsiah E. Increased levels of a-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. Neuroimmunal 88,105–110 (1998).
   PubMed Web of Science ®Google Scholar
• Travis J, Salvelsen GS. Human plasma proteinase inhibitors. Ann. Rev Biochem. 52,655–709 (1983).
   PubMed Web of Science ®Google Scholar
• Abraham CR, Selkoe DJ, Potter H. Immunochemical identification of the serine protease inhibitor, alpha-1-antichymotrypsin in the brain amyloid deposits. c1152, 487–501 (1988).
   Google Scholar
• •Important paper describing the presence of acute phase protein in the AD brain.
   Google Scholar
• Eriksson S, Janciauskiene S, Lannfelt L. Alpha-l-antichymotrypsin regulates Alzheimer 3-amyloid peptide fibril formation. Proc. Natl Acad. Sci USA 92, 2313–2317 (1995).
   Google Scholar
• Fraser PE, Nguyen JT, McLachlan DR, Abraham CR, Kirschner DA. Alpha-1-antichymotrypsin binding to Alzheimer AP peptides is sequence specific and induces fibril disaggregation in vitro I Neurochem. 6,298-305 (1993).
   Google Scholar
• Ma J, Yee A, Brewer HB, Das S, Potter H. Amyloid-associated protein alpha-1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer 3-protein into filaments. Nature 372,92–94 (1994).
   Google Scholar
• Lieb K, Fiebich BL, Schaller H, Berger M, Bauer J. Interleukin-1 beta and tumor necrosis factor-alpha induce expression of alpha-l-antichymotrypsin in human astrocytoma cells by activation of nuclear factor-kappa B. I Neurochem. 67,2039-2044 (1996).
   Google Scholar
• Kordula T, Rydel RE, Brigham EF, Horn F, Heinrich PC, Travis J. Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate alpha-1-antichymotrypsin expression in human cortical astrocytes. I Biol. Chem. 237, 4112–4118 (1998).
   Google Scholar
• Licastro F, Parnetti L, Morini MC et al Acute phase reactant alpha-l-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer's disease. Alzheimer: Dir. Assoc. Dirorrler9, 112–118 (1995).
   Google Scholar
• Altstiel LD, Lawlor B, Mohs R et al. Elevated alpha- 1-antichymotrypsin serum levels in a subset of non-demented first-degree relatives of Alzheimer's disease patients. Dementia 6,17–20 (1995).
   PubMedGoogle Scholar
• Furby A, Leys D, Delacourte A, Buee L, Soetaert G, Petit H. Are alpha-1-antichymotrypsin and inter-alpha-trypsin inhibitor peripheral markers of Alzheimer's disease?' Neural. Neurosurg. Bychiatry 54, 469 (1991).
   Google Scholar
• Pirtilla T, Mehta PD, Frey H, Wisniewski HM. Alpha-l-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. Neurobial Aging 15, 313–317 (1994).
   PubMedGoogle Scholar
• Licastro F, Pedrini S, Davis LJ et al Alpha-1-antichymotrypsin and oxidative stress in the peripheral blood from patients with probable Alzheimer's disease: a short-term longitudinal study. Alzheimer Dis. Assoc. Disarler 15,51–55 (2001).
   Google Scholar
• Licastro F, Pedrini S, Caputo L et al Increased plasma levels of interleukin-1, interleukin-6 and a-l-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signal from the brain? Neuroimmunal 103,97–102 (2000).
   Google Scholar
• •First paper suggesting a probable brain origin of selected altered immune molecules in the peripheral blood of AD patients.
   Google Scholar
• Rosenberg RN. The molecular and genetic basis of AD: the end of the beginning. Neurology54, 2045–2054 (2000).
   PubMed Web of Science ®Google Scholar
• Papassotiropoulos A, Bagli M, Jessen F et al A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk of sporadic Alzheimer's disease. Ann. Neural. 45,666-668 (1999).
   Google Scholar
• •First paper describing a genetic association of IL-6 with AD.
   Google Scholar
• Licastro F, Grimaldi LME, Pedrini S et al. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in the blood and brain. Neurobial Aging (submitted) (2002).
   Google Scholar
• Grimaldi LME, Casadei VM, Ferri C et al Association of early-onset Alzheimer's disease with an interleukin-la gene polymorfism. Ann. Neural. 47,361–365 (2000).
   PubMed Web of Science ®Google Scholar
• •First paper describing a genetic association of IL-I with AD.
   Google Scholar
• Nicoll JAR, Mrak RE, Graham DI et al. Association of interleukin-1 gene polymorfism with Alzheimer's disease. Ann. Neural. 47,365-368 (2000).
   Google Scholar
• Rebeck GW. Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease. Neurosci. Lett. 293,75-77 (2000).
   Google Scholar
• Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST APOE 4 associated Alzheimer's disease risk is modified by alpha-l-antichymotrypsin polymorfism. Nat. Genet. 10,486-488 (1995).
   Google Scholar
• Haines JL, Prochard ML, Saunders AM et al No genetic effect of alpha-1-antichymotrypsin in Alzheimer's disease. Genomic533, 53–56 (1996).
   Google Scholar
• Licastro F, Pedrini S, Govoni M et al Apolipoprotein E and alpha-1- antichymotrypsin allele polymorphism in sporadic and familiar Alzheimer's disease. Neurosci Lett. 270,129–132 (1999).
   PubMed Web of Science ®Google Scholar
• Murphy GM, Sullivan EV, Gallagher-Thompson D et al No association between the alpha- 1-antichymotrypsin A allele and Alzheimer's disease. Neurology 19,1313–1316 (1997).
   Google Scholar
• Durany N, Ravid R, Riederer P, Cruz- Sanchez FE Increased frequency of the alpha-l-antichymotrypsin T allele in cerebral amyloid angiopathy. Neuropathology20, 184–189 (2000).
   PubMed Web of Science ®Google Scholar
• Nilsson LN, Bales KR, DiCarlo G etal. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J: Neumsci. 21, 1444–1451 (2001).
   Google Scholar
• Mucke L, Yu GQ, McConlogue L, Rockenstein EM, Abraham CR, Masliah E. Astroglial expression of human alpha-1-antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice. Am.J. Athol 157, 2003-2010 (2000).
   Google Scholar
• Licastro F, Campbell IL, Kincaid C et al A role for apoE in regulating the levels of alpha-1-antichymotrypsin in the aging mouse brain and in Alzheimer's disease. Am. Pathol 155, 869–875 (1999).
   Google Scholar
• Licastro F, Pedrini S, Ferri C et al Gene polymorphism affecting alpha-1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann. Neural. 48, 388–391 (2000).
   Google Scholar
• Morgan K, Licastro F, Tilley L, Ritchie A, Pedrini S, Kalsheker N. Polymorphism inthe alpha-1-antichymotrypsin (ACT) gene promoter: effect on expression in transfected glial and liver cell lines and plasma ACT concentrations. Hum. Genet. 109, 303–310 (2001).
   Google Scholar
• Griffin WST, Nicoll JAR, Grimaldi LME, Sheng JG, Mrak RE. The pervasiveness of interleukin-1 in Alzheimer pathogenesis: a role for specific polymorphisms in disease risk. Exp. Gerontol 35, 481–487 (2000).
   Google Scholar
• Thorns V, Licastro F, Masliah E. Locally reduced levels of acidic FGF lead to decreased expression of 28.1(Da caldinbin and contribute to the selective vulnerability of neurons in the entorhinal cortex in Alzheimer's disease. Ailrropathology21, 203–211 (2001).
   Google Scholar
• Sheng JG, Mrak RE, Griffin WST. Glial- neuronal interactions in Alzheimer's disease: progressive association of IL-1I3 microglia and S100a astrocytes with neurofibrillary tangle stages. I Neuropathol Exp. Neural. 56, 285–290 (1997).
   Google Scholar
• Sheng JG, Zhu SG, Griffin WST, Mrak RE. Interleukin-1 promotes expression and phosphorylation and tau protein in viva Exp. Neural. 163, 388–391 (2000).
   Google Scholar
• Schenk D, Barbour R, Dunn W et al. Immunization with amyloid beta attenuates Alzheimer-disease-like pathology in PDAPP mouse. Nature 400, 173–177 (1999).
   PubMed Web of Science ®Google Scholar
• Morgan D, Diamond DM, Gottschall PE et al A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982–985 (2000).
   PubMed Web of Science ®Google Scholar
• Janus C, Pearson J, Mclaurin J et al A beta peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 408, 979–982 (2000).
   PubMed Web of Science ®Google Scholar
• •Two papers suggesting a close relationship between immune responses and cognitive decline in animal models of AD.
   Google Scholar